Chanakya Nath Kundu

Professor, Research Dean

Prof. Chanakya Nath Kundu is presently working as a Professor and Research Dean at the School of Biotechnology, KIIT-DU. He completed his B.Sc. (Chemistry) and M.Sc. (Biochemistry) in 1994 and 1996, respectively. He completed his Ph.D. from Indian Institute of Chemical Biology (IICB, a unit CSIR, Govt. of India), Kolkata in 2002. Before joining as an Assistant Professor at KIIT University in 2008, he successfully completed his post-doctoral training at different universities and research institutes in USA, such as Texas A&M University, Texas, University of Florida, Gainesville, Florida and Cleveland Clinic Foundation, Cleveland, Ohio in the field of molecular cancer signaling from 2001 to 2008. Presently, his research focuses on the study of the molecular mechanism of metastasis, drug resistance and cancer relapse and their signaling pathways. He has identified a novel protein (NECTIN-4, a pvrl-4 encoded gene), which is responsible for metastasis and angiogenesis in varieties of cancer. He has developed a hybrid nanoparticle, which specifically kills the cancer stem cells without affecting the normal cells. He has already published more than 100 international/national peer-reviewed articles in very reputed journals and successfully completed multiple Govt. of India funded projects. He has filed eight patents and written several book chapters. 16 research scholars have already received Ph.D. degree under his supervision. He is the editorial board member of several international peer-reviewed journals. He has received multiple awards from different scientific research organizations for his outstanding contribution in biological science, such as Drs. Kunti and Om Prakash Oration Award, ICMR, DBT-CREST fellowship, Young Biomedical Fellowship award, ICMR, Best Faculty award-KIIT-DU, etc.

Profile Links

Email :
[email protected]
Scopus Id :
6602388770
Google Scholar :
https://scholar.google.co.in/citations?user=mCn-uDoAAAAJ&hl=en

Social Links

Educational Qualification
Ph.D.

Projects
  1. Talazoparib (BMN-673) a PARP inhibitor and quinacrine synergistically induces apoptosis in buccal mucosa CSCs by inhibiting the DNA repair cascade (PI) (ICMR funded, 2019-2022)
  2. Targeting Sarcolipin-based muscle energy expenditure to provide protection against type-II diabetes (Co-PI) (DBT funded, 2019-2022)
  3. Synthesis and evaluation of 198 Au based nanoparticulate system for radiotherapy against breast cancer (Co-PI) (BRNS funded, 2018-2021)
  4. Olaparib (AZD2281) a PARP inhibitor and curcumin synergistically induces apoptosis in oral cancer stem cells by inhibiting the DNA repair cascade (PI) (DBT funded, 2018-2021)
  5. Quinacrine and silver based hybrid nanoparticle caused apoptosis in oral cancer stem cells by inhibiting induction of base excision repair pathway (PI) (ICMR funded, 2018-2021)
  6. Study of estrogen receptor alpha (ER-a) in breast cancer patients with reference to local population (Co-PI) (DBT funded, 2013-2016)
  7. Study the role of Nectin-4 (a pvrl 4 encoded gene) as a biomarker for angiogenesis in metastatic head and neck squamous cell carcinoma (HNSCC) (PI) (DST-SERB funded, 2017-2020)
  8. Development of a potent anti-cervical cancer drug using bioactive small molecule Quinacrine- nanoparticle (PI) (ICMR funded, 2015-2018)
  9. Evaluate the mechanism of resveratrol mediated apoptosis in cigarette smoke induced breast cancer (PI) (DBT funded, 2010-2013)
  10. Improvement of 5 flurouracil mediated cytotoxicity of colon cancer cells by novel approaches (PI) (ICMR-funded, 2010-2013)
  11. Evaluation of anti-cancer potentiality of bio-active compound quinacrine in preclinical models of breast cancer (PI) (ICMR-funded, 2009-2012)

    Administrative Responsibility
    ADMINISTRATIVE JOBS: 1. Dean (Research) 2. Design of MSC Biotechnology, Applied Microbiology and M Tech Biotechnology Syllabus 3. Served R&D head of the department 4. Course coordinator of MSC Biotechnology 5. Coordinator of NET/GATE preparation training, etc. 6. Member of Board of Studies in different Department in the University

    Memberships
    1. Associate member: American Association for Cancer Research
    2. Life time member: Indian Association for Cancer Research
    3. Life time member: Society of Biological Science
    4. Life time Member: All India Council for Technical Education
    5. Life time member: Indian Science Congress


    Outreach Activity
    1. Design of MSC Biotechnology, Applied Microbiology and M.Tech Biotechnology Syllabus
    2. Member of Board of Studies
    3. Course co-ordinator of MSc Biotechnology
    4. Co-ordinator of NET/GATE preparation training, etc.

Journals/Conferences :
1. Das B, Dash SR, Patel H, Sinha S, Bhal S, Paul S, Das C, Pradhan R, Ahmed I, Goutam K, Kundu CN*. Quinacrine inhibits HIF-1α/VEGF-A mediated angiogenesis by disrupting the
interaction between cMET and ABCG2 in patient-derived breast cancer stem cells. Phytomedicine. 2023 Aug;117:154914. doi: 10.1016/j.phymed.2023.154914. Epub 2023 Jun 3.
PMID: 37321076.
2. Das B, Sethy C, Chatterjee S, Dash SR, Sinha S, Paul S, Goutam K, Kundu CN*. Quinacrine inhibits cMET-mediated metastasis and angiogenesis in breast cancer stem cells. J Cell
Commun Signal. 2023 May 10. doi: 10.1007/s12079-023-00756-9. Epub ahead of print. PMID: 37162635.
3. Dash SR, Das B, Das C, Sinha S, Paul S, Pradhan R, Kundu CN*. Near-infrared enhances antiangiogenic potentiality of quinacrine-gold hybrid nanoparticles in breast cancer stem cells via deregulation of HSP-70/TGF-β, Nanomedicine (Lond.) (Epub ahead of print). (I.F. 6.096) [ISSN 1743-5889; UGC: 18107].
4. Pradhan R, Paul S, Das B, Sinha S, Dash SR, Mandal M, Kundu CN*. Resveratrol nanoparticle attenuates metastasis and angiogenesis by deregulating inflammatory cytokines through inhibition of CAFs in oral cancer by CXCL-12/IL-6-dependent pathway. J Nutr Biochem. 2023 Mar;113:109257. doi: 10.1016/j.jnutbio.2022.109257. Epub 2022 Dec 24. PMID: 36572069. (I.F. 6.117) [ISSN: 0955-2863; UGC: 46532].
5. Nayak D, Paul S, Das C, Bhal S, Kundu CN. Quinacrine and Curcumin in combination decreased the breast cancer angiogenesis by modulating ABCG2 via VEGF A. J Cell Commun
Signal. 2022 Nov 3. doi: 10.1007/s12079-022-00692-0. Epub ahead of print. PMID: 36326988. (I.F. 5.908) [ISSN: 1873-9601, UGC: 12916] 6. Paul S, Sinha S, Kundu CN. Targeting cancer stem cells in the tumor microenvironment: An emerging role of PARP inhibitors. Pharmacol Res. 2022 Sep 5:106425. doi: 10.1016/j.phrs.2022.106425. Epub ahead of print. PMID: 36075511. (I.F. 10.334) [ISSN: 1043-6618, UGC: 19657] 7. Sinha S, Chatterjee S, Paul S, Das B, Dash SR, Das C, Kundu CN. Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous
recombination repair pathway. Exp Cell Res. 2022 Sep 6;420(1):113338. doi: 10.1016/j.yexcr.2022.113338. Epub ahead of print. PMID: 36075449. (I.F. 4.145) [ISSN:
144827, UGC: 7487] 8. Chatterjee S, Dhal AK, Paul S, Sinha S, Das B, Dash SR, Kundu CN. Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by
PARP-1 trapping. J Cancer Res Clin Oncol. 2022 Aug 13. doi: 10.1007/s00432-022-04269-7. Epub ahead of print. PMID: 35962813. (I.F. 4.322) [ISSN: 0171-5216, UGC: 12884] 9. Sethy C, Kundu CN*. PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells.
Toxicol Appl Pharmacol. 2022 Feb 1;436:115860. doi: 10.1016/j.taap.2021.115860. Epub 2022 Jan 5. PMID: 34998856. (I.F. 4.46) [ISSN: 0041-008X, UGC: 2195] 10. Dash SR, Chatterjee S, Sinha S, Das B, Paul S, Pradhan R, Sethy C, Panda R, Tripathy J, Kundu CN*. NIR irradiation enhances the apoptotic potentiality of quinacrine-gold hybrid nanoparticles by modulation of HSP-70 in oral cancer stem cells. Nanomedicine: Nanotechnology, Biology and Medicine. 2022 Feb 1;40:102502. doi: 10.1016/j.nano.2021.102502. Epub 2021 Nov 26. PMID: 34843984. (I.F. 6.458) [ISSN: 1549- 9634; UGC: 37212] 11. Chatterjee S, Sinha S, Kundu CN*. Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy. Eur J Pharmacol. 2021 Sep 20;911:174516. doi: 10.1016/j.ejphar.2021.174516. Epub ahead of print. PMID: 34547246. (I.F. 5.195) [ISSN: 0014-2999; UGC: 28806] 12. Sinha S, Molla S, Kundu CN*. PARP1-modulated chromatin remodeling is a new target for cancer treatment. Med Oncol. 2021 Aug 25;38(10):118. doi: 10.1007/s12032-021-01570-2. PMID: 34432161. (I.F. 3.738) [ISSN: 0013-570560; UGC: 4282] 13. Sinha S, Kundu CN*. Cancer and COVID-19: Why are cancer patients more susceptible to COVID-19? Med Oncol. 2021 Jul 24;38(9):101. doi: 10.1007/s12032-021-01553-3. PMID:
34302557. (I.F. 3.738) [ISSN: 0013-570560; UGC: 4282] 14. Molla S, Chatterjee S, Sethy C, Sinha S, Kundu CN*. Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly. DNA Repair (Amst). 2021 Jun 10;105:103157. doi: 10.1016/j.dnarep.2021.103157. Epub ahead of print. PMID: 34144488. (I.F. 4.354) [ISSN: 1568-7864; UGC:13326] 15. Sethy C, Goutam K, Das B, Dash SR, Kundu CN*. Nectin-4 promotes lymphangiogenesis and lymphatic metastasis in breast cancer by regulating CXCR4-LYVE-1 axis. Vascul Pharmacol. 2021 May 1:106865. doi: 10.1016/j.vph.2021.106865. Epub ahead of print. PMID: 33945869. (I.F. 5.738) [ISSN: 1537-1891; UGC: 35527] 16. Pradhan R, Chatterjee S, Hembram KC, Sethy C, Mandal M, Kundu CN*. Nano formulated Resveratrol inhibits metastasis and angiogenesis by reducing inflammatory cytokines in oral cancer cells by targeting tumor associated macrophages. The Journal of Nutritional Biochemistry. 2021 Jun;92:108624. doi: 10.1016/j.jnutbio.2021.108624. Epub 2021 Mar 8. PMID: 33705943. (I.F. 6.117) [ISSN: 0955-2863; UGC: 46532] 17. Sethy C, Kundu CN*. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother. 2021 Jan 21. 2021 May;137:111285. doi: 10.1016/j.biopha.2021.111285. PMID: 33485118. (I.F. 7.419) [ISSN: 0753-3322; UGC: 14808] 18. Chatterjee S, Sinha S, Molla S, Hembram KC, Kundu CN*. PARP inhibitor Veliparib (ABT- 888) enhances the anti-angiogenic potentiality of Curcumin through deregulation of NECTIN-4 in oral cancer: Role of nitric oxide (NO). Cell Signal.  2021 Apr;80:109902. doi: 10.1016/j.cellsig.2020.109902. Epub 2020 Dec 26. PMID: 33373686. (I.F. 4.85) [ISSN: 0898- 6568; UGC: 5282] 19. Chatterjee, Subhajit, and Chanakya Nath Kundu. "Nanoformulated quinacrine regulates NECTIN-4 domain specific functions in cervical cancer stem cells." European Journal of Pharmacology 883 (2020): 173308.
20. Hembram, Krushna Chandra, et al. "Quinacrine based gold hybrid nanoparticle caused apoptosis through modulating replication fork in oral cancer stem cells." Molecular Pharmaceutics (2020).
21. Nayak, Deepika, et al. "Quinacrine and curcumin synergistically increased the breast cancer stem cells death by inhibiting ABCG2 and modulating DNA damage repair pathway." The International Journal of Biochemistry & Cell Biology 119 (2020): 105682.
22. Sethy, Chinmayee, et al. "Clinical significance of a pvrl 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse." Journal of Cancer Research and Clinical Oncology 146.1 (2020): 245-259.
23. Nayak, Anmada, et al. "Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation." Cellular Oncology 42.2 (2019): 157-171.
24. Satapathy, Shakti Ranjan, et al. "Metallic gold and bioactive quinacrine hybrid nanoparticles inhibit oral cancer stem cell and angiogenesis by deregulating inflammatory cytokines in p53 dependent manner." Nanomedicine: Nanotechnology, Biology and Medicine 14.3 (2018): 883- 896.
25. Siddharth, Sumit, et al. "Nectin-4 is a breast cancer stem cell marker that induces WNT/β- catenin signaling via Pi3k/Akt axis." The International Journal of Biochemistry & Cell Biology 89 (2017): 85-94.
26. Das, Sarita, et al. "Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade." Oncotarget 8.1 (2017): 248.

Books :
1. Chatterjee S., Patil C.R., Kundu C.N*. (2021) An Overview of Antioxidative Anticancer Therapies with Reference to the Cancer Stem Cells. In: Chakraborti S. (eds) Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Springer, Singapore. https://doi.org/10.1007/978-981-16-1247-3_48-1
2. Kundu CN, Mohapatra P, Preet R, Das D, Satapathy SR. (2014). “Anticancer Drugs Designed by Mother Nature: An Old Lock Needs a New Key.” Advances in Biochemistry & Biotechnology Volume 2 Ed. Biplab Sarkar and Chiranjib Chakraborty. New Delhi: Daya Publishing House, 99- 120.
3. Kundu CN*, Majumder GC, Preet R. (2010), Cryopreservation of Spermatozoa. Recent Biotechnological advancement in gamete preservation technology, Chapter 15, page- 277-302, IGI global publication, USA.
4. Saha S., Das K., Banerjee S., Nath D., Maiti A., Barua M., Kundu CN*., Mandal M., Chakrabarty J., Jaiswal B. S.,Bhattacharyya D., Chattopadhyay D., Dungdung S. R., Majumder G. C. (2009): Biochemical Parameters of Sperm Flagellar Motility Initiation and Regulation. Advanced Medicare (Ed. R. Sen), B. I. Publication Pvt. Ltd, New Delhi

Cancer Biology Laboratory

Research Thrust Area:

Dr. Chanakya Nath Kundu’s (CNK) laboratory is focused on multidisciplinary aspects of Tumor Biology. This broad spectrum of research includes targeting angiogenesis and metastasis, inducing DNA damage, and inhibiting DNA repair by using several bioactive or synthetic compounds. CNK group initially focused on targeting cancer stem cells (CSCs) as they are responsible for tumor relapse and drug resistance. Presently, his laboratory focuses on the molecular mechanism of metastasis, drug resistance and cancer relapse and their signaling pathways. His team identified a novel protein, NECTIN-4, which is responsible for angiogenesis including lymph-angiogenesis, metastasis and lymph node metastasis, tumor relapse, DNA repair in different types of cancer. His team has also developed a hybrid nanoparticle which specifically kills the cancer stem cells without affecting the normal cells. CNK laboratory is extensively working in the above-mentioned domains of cancer biology for more than 10 years.

CNK laboratory is funded by different Govt. funding agencies like DBT, DST-SERB, ICMR-
BMS, ICMR-NCD, BRNS etc.

Patents

  1. N-Fused Aminoimidazoles as Novel Topoisomerase IIα-Targeting Anticancer Agents. Guchhait SK, Kundu CN, Banerjee UC, Baviskar A, Madaan C, Agarwal A, Preet R, Mohapatra P, (Indian Patent Pending, Appl # 91/DEL/2011).
  2. 2,4-Diamino Substituted And 4-Amino, 2-Oxy Disubstituted Pyrimidine Derivatives, A Process and Uses. Patel H M, Pawara R H, Patil CR, Kundu CN, Nayak D. 2/1421/MUM
  3. Acrylmide brearing quinazolin in4(3H)-one derivatives. A process and uses thereof. Patel H M, Kundu CN Pawara R H, Patil C R, , Nayak D. 2/1422/MUM
  4. 4-amino-2-oxy disubstitututed prymidine derivatives, a process and uses thereof. Patel H M, Kundu CN, Pawara RH, Patil C R, Nayak D, Iqrar A. 2/1420/MUM
  5. Quinacrine-gold hybrid nanoparticle and NIR irradiation for treatment of oral cancer. Satapathy SR, Dash SR, Kundu CN. Application no. 202231059841. Publication date (U/S 11A) – 4/11/2022.
  6. Nectin-4 is a soluble biomarker for the detection of cancer. Sethy C, Kundu CN. Application no. 202231059837. Publication date (U/S 11A) – 4/11/2022.
  7. Polysaccharide-based wound healing patch. Das M, Das B, Kundu CN, Tripathy J. Application no. 202231059838. Publication date (U/S 11A) – 4/11/2022.
  8. A novel application of i-prf for human dental pulp stem cells proliferation. Panda B, Patri G, Kundu CN, Das B. Application no. 202331016204. Publication date (U/S 11A) – 24/03/2023.

Collaborators

International

  1. Prof. Michael D Wyatt: Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, USA.
  2. Prof. Satya Narayan: Department of Anatomy and Cell Biology, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.

National

  1. Prof. Prasad V. Bharatam: Professor & Head, Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER) S.A.S. Nagar Sector 67, S.A.S. Nagar (Mohali)- 160062, Punjab (India).
  2. Prof. Chandragouda R Patil: Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University.
  3. Dr. Sankar Guchhait: Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S. A. S. Nagar, Mohali, Punjab 160062, India.
  4. Dr. Harun Patel: Department of Pharmacology, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur- 425405, Dist. Dhule, Maharashtra, India.
  5. Dr. Kunal Goutam: Department of Surgical Oncology, Acharya Harihar Regional Cancer Centre, Cuttack, 753007, Odisha, India.
  6. Dr. Niranjan Rout: Department of Oncopathology, Acharya Harihar Regional Cancer Centre, Cuttack, 753007, Odisha, India.
  7. Dr. Jyochanamayi Panda: Obstetrics & Gynecology Department, Kalinga Institute of Medical Sciences, Kalinga Institute of Industrial Technology, Deemed to be University, Bhubaneswar, Odisha, 751024, India.
  8. Dr. Jasaswini Tripathi: School of Applied Sciences, Kalinga Institute of Industrial Technology (Deemed to be University), Campus-11, Patia, Bhubaneswar, Odisha 751024, India.
  9. Dr. Satyabrata Si: School of Chemical Technology, KIIT University, Campus-11, Bhubaneswar, Odisha 751024, India.
  10. Dr. Naresh Ch Bal: School of Biotechnology, KIIT University, Campus-11, Bhubaneswar, Odisha 751024, India.
  11. Dr. Birendra Kumar Bindhani: Plant Biotechnology and Nanotechnology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (Deemed to be University), Campus-Patia, Bhubaneswar, Odisha 751024, India.
  12. Prof. N.S. Hari Narayana Moorthy: Department of Pharmacy, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh, India.
  13. Dr. C. Karthikeyan: Department of Pharmacy, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh, India.

Current Lab Members

Rajalaxmi Pradhan, Ph.D. Candidate
Rajalaxmi is from Nayagarh, Odisha. She has a master’s degree in Biotechnology from Ravenshaw University, Cuttack, Odisha. She is pursuing her doctoral degree on studying the role of cytokines and chemokines in the induction of cancer stem like cells (CSCs) in oral cancer cells niche and evaluated the mechanism of Resveratrol nanoparticle (Res- NP) mediated-reduction of CSCs properties in cells by using several in vitro, ex vivo and in vivo mice xenograft model system. She is funded by DST- INSPIRE-fellowship.

Email: [email protected]  [email protected]

Biswajit Das, Ph.D. Candidate

Biswajit hails from Midnapore, West Bengal, India. He has earned his M.Sc. in Zoology from Vidyasagar University. He has qualified CSIR-NET, Life Science. His current study deals with the role of Quinacrine on several cancer stem cell signaling proteins and how these signaling proteins are involved in angiogenesis and metastasis, the two crucial hallmarks for cancer progression. Biswajit’s experimental work is based on in vitro, in vivo and ex vivo (patient sample) model systems. His work is funded by ICMR-NCD-III project of Dr. C. N. Kundu.

Email: [email protected]; [email protected]

Saptarshi Sinha, Ph.D. Candidate

Saptarshi is from Kolkata, West Bengal, India. He earned his M.Sc. in Biochemistry from Bangalore University, India. He also earned a Postgraduate Diploma in Cell and Molecular Bioscience and worked as a research assistant at Victoria University of Wellington, New Zealand. In his doctoral research at KIIT-DU, he is working on the development of a combination of chemotherapeutic agents to target breast cancer cells by inhibiting the DNA repair pathways. He is using in vitro, ex vivo and in vivo pre-clinical model systems to address his research questions. His research is funded by ICMR-SRF fellowship.

Email: [email protected];  [email protected]

Somya Ranjan Dash, Ph.D. Candidate

Somya is from Bhubaneswar, Odisha, India. He has earned his Master of Science in Biotechnology (Sponsored by DBT, Govt. of India) from P.G. Department of Biotechnology, Utkal University, Bhubaneswar, Odisha, India. He is currently working in the area of Photothermal Therapy for cancer using multifunctional hybrid nanoparticles. He uses various in vitro and in vivo approaches to understand the mechanical actions of these nanoparticles in Photothermal Therapy. He has qualified GATE Life science examination and has been funded by DST-INSPIRE, Department of Science and Technology, Govt. of India to pursue his research work.

Email: [email protected]

Subarno Paul, PhD Candidate

Subarno belongs to Kolkata, West Bengal, India. He has completed his M.Sc. in Biotechnology from School of Biotechnology, KIIT deemed to be University. He is working on the combination of a bioactive compound and clinically trialled agent to target DNA repair in order to make effective therapeutics in colorectal cancer. His work is mainly based on evaluating the anti-angiogenic and anti-metastatic potentiality of the combination therapy in different in vitro, ex vitro, ex vivo and in ovo     model systems. His work is funded by DBT funded project of Dr. C. N. Kundu.

Email: [email protected]; [email protected]

Subhasmita Bhal, Ph.D. Candidate

Subhasmita comes from Bhadrak, Odisha, India. She has earned her M.Sc. in Biotechnology (Gold medalist) from Fakir Mohan University, Balasore. She is working on targeting the crosstalk of various cancer stem-like cells (CSCs) signaling pathways. Her current study focusses on deregulating the interaction of Wnt and Hh pathways using a nano-formulated Resveratrol (Res-Nano). She is performing in vitro, in vivo, in ovo and ex vivo to decipher the study. Her work is supported by DST-SERB project of Dr. C. N. Kundu.

Email: [email protected];[email protected]

Chinmay Das, Ph.D. Candidate

Chinmay belongs to Mayurbhanj, Odisha, India. He pursued a Master of Science in Biotechnology from Ravenshaw University, Cuttack, Odisha, India. He is currently working on a combination of drugs that can induce apoptosis in buccal mucosa cancer cells. He is doing various in vivo and in vitro experiments to identify the molecular mechanisms of these combined drugs. He has qualified GATE Life science and his work has been funded by ICMR funded project of Dr. C. N. Kundu.

Email: [email protected]m

Sushree Subhadra Acharya, Ph.D. Candidate

Sushree is from Nayagarh, Odisha, India. She has completed her Master of Science in Biochemistry from P.G. Department of Biochemistry, North Orissa University, Mayurbhanj, Odisha, India. Currently, she is working in the area of Cancer Immunology. Her work is focused on finding the cancer progressive properties of immune cells in the Tumor Microenvironment using in vitro, in ovo, ex vivo, in vivo mice xenograft model systems. She has been funded by DST-INSPIRE, Department of Science and Technology, Govt. of India to pursue her research work. Email: [email protected]; [email protected]

 

Bhaskarjyaa Chatterjee, Research Assistant

Bhaskarjyaa is from Kolkata, West Bengal. He earned his Master of Technology (M.Tech) in Biotechnology (Sponsored by DBT, Govt of India) from Anna University, Chennai, Tamil Nadu. He is working in the area of cancer immunology. His work is related to how a natural bioactive compound inhibits metastasis and angiogenesis in oral cancer stem cells  through inhibition of tumor-associated macrophages derived inflammatory cytokines. His work is supported by ICMR funded project of Dr. C.N. Kundu.

Email: [email protected]

Ph.D. degree awarded:

  1. Dr. Gopal Kumar Choudhary, Assistant Professor, School of Biotechnology, KIIT, Odisha, India
  2. Dr. Ranjan Preet, Senior Scientist, Deciphera Pharmaceuticals, Lawrence, Kansas, USA
  3. Dr. Purusottam Mohapatra, DBT Ramalingaswami Fellow, NIPER-Guwahati, India
  4. Dr. Maitree Choudhuri, Principal, Kanchrapara Govt. Engineering College
  5. Dr. Dipon Das, Research Scientist, Harvard Medical School, USA
  6. Dr. Shakti Ranjan Satapathy, Research Engineer, Lund University, USA
  7. Dr. Sumit Siddharth, Senior Research Investigator, Syngene International Limited, India
  8. Dr. Sarita Das, Research Associate, Indian Association for the Cultivation of Science, Kolkata
  9. Dr. Anmada Nayak, Assistant Professor, Odisha University of Technology and Research, Bhubaneswar, Odisha.
  10. Dr. Krushna Chandra Hembram, Technical Superintendent, IIT Hyderabad, India
  11. Dr. Sefinew Molla Bitew, Postdoctoral Fellow, Wayne State University, USA
  12. Dr. Chinmayee Sethy, Postdoctoral Fellow, IIT Delhi, India.
  13. Dr. Subhajit Chatterjee, Postdoctoral Fellow, National Cancer Institute, National Institute of Health (NIH), USA
  14. Dr. Deepika Nayak, Postdoctoral Fellow
  15. Dr. Mansi Priyadarshini, Postdoctoral Fellow in USA. (Dr. C.N. Kundu was Co-PI)
  16. Dr. Bipasa Kar, Postdoctoral Fellow in Germany. (Dr. C.N. Kundu was Co-PI)

Extramural Funding 

Sl.No

Title of the project

Agency

Present status

Role (PI/Co-PI)     
1 Evaluation of anti-cancer potentiality of bio-active compound quinacrine in preclinical models of breast cancer

ICMR

Completed
01-08-2009 to 31-07-2012

PI

2 Improvement of 5-fluorouracil mediated cytotoxicity of colon cancer cells by novel approaches

ICMR

Completed
01-04-2010- to 31-03-2013

PI

3 Evaluate the mechanism of resveratrol mediated apoptosis in cigarette smoke induced breast cancer

DBT

Completed
01-04-2010 to 31-03-2013

PI

4 Development of a potent anti-cervical cancer drug using bioactive small molecule Quinacrine- nanoparticle

ICMR

Completed
01-04-2015 to 31-03- 2018

PI

5 Study the role of Nectin-4 (a pvrl 4 encoded gene) as a biomarker for angiogenesis in metastatic head and neck squamous cell carcinoma (HNSCC).

DST-SERB

Completed
01-04-2017 to 31-03-2020

PI

6 Study of estrogen receptor alpha (ER-a) in breast cancer patients with reference to local population

DBT

2013-2016

Co-PI

7 Quinacrine and silver-based hybrid nanoparticle caused apoptosis in oral cancer stem cells by inhibiting induction of base excision repair pathway

ICMR

2018-2021

PI

8 Olaparib (AZD2281) a PARP inhibitor and curcumin synergistically induces apoptosis in oral cancer stem cells by inhibiting the DNA repair cascade.

DBT

2018-2021

PI

9 Synthesis and evaluation of 198 Au based nanoparticulate system for radiotherapy against breast cancer

BRNS

2018-2023

Co-PI

10 Targeting Sarcolipin-based muscle energy expenditure to provide protection against type-II diabetes

DBT

2019-2023

Co-PI

11 Talazoparib (BMN-673) a PARP inhibitor and quinacrine synergistically induces apoptosis in buccal mucosa CSCs by inhibiting the DNA repair cascade

ICMR

2019-2023

PI

12 Quinacrine inhibits metastasis and angiogenesis in oral cancer stem cells through the inhibition of tumor associated macrophages derived inflammatory cytokines.

ICMR

2023 -ONGOING

PI

OPEN POSITIONS:

Post-doc position

  1. If you are interested, send an e-mail ([email protected]) to me with your CV. Please mention your specific practical skills, instrument handling experience, and a one-page write-up about your thesis work. Candidates with experience in mammalian cell culture, and cancer cell biology will be preferred.
  2. I can also help you write a research proposal that can be submitted to any funding agency (DBT, CSIR, SERB, or ICMR) that offers a postdoctoral fellowship. 

PhD position

  1. If you are interested, send an e-mail ([email protected]) to me with your CV. Please mention your specific practical skills, instrument handling experience, and a one-page write-up about your thesis work. Candidates with experience in mammalian cell culture, and cancer cell biology will be preferred. Candidates with NET/GATE/INSPIRE fellowship will be given preference.